Metastatic NSCLC Clinical Trials

4 recruiting

Metastatic NSCLC Trials at a Glance

14 actively recruiting trials for metastatic nsclc are listed on ClinicalTrialsFinder across 6 cities in 15 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Angers, Paris, and Lyon. Lead sponsors running metastatic nsclc studies include Jiangsu Hansoh Pharmaceutical Co., Ltd., Elephas, and Dr Arvindran A/L Alaga.

Browse metastatic nsclc trials by phase

Treatments under study

About Metastatic NSCLC Clinical Trials

Looking for clinical trials for Metastatic NSCLC? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic NSCLC trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic NSCLC clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting

Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)

Metastatic Lung CancerMetastatic NSCLCMetastatic Small Cell Lung Cancer
GFPC Investigation1,000 enrolled46 locationsNCT07243132
Recruiting
Phase 2

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

Metastatic NSCLC - Non-Small Cell Lung Cancer
Swiss Cancer Institute156 enrolled17 locationsNCT07020065
Recruiting
Phase 2

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc.220 enrolled80 locationsNCT05967689
Recruiting
Phase 2

Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.

Metastatic NSCLC - Non-Small Cell Lung Cancer
Fondazione Ricerca Traslazionale33 enrolled1 locationNCT07392658
Recruiting

Large Granular Lymphocytes in mNSCLC Treated With Nivolumab

Metastatic NSCLC - Non-Small Cell Lung Cancer
Necmettin Erbakan University50 enrolled1 locationNCT07363811
Recruiting

Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform

NSCLC (Non-small Cell Lung Cancer)Metastatic NSCLC - Non-Small Cell Lung Cancer
Elephas200 enrolled7 locationsNCT05478538
Recruiting
Phase 2

Impact of Circadian Rhythm on Immunotherapy

Advanced/Metastatic NSCLC
Liza Villaruz, MD350 enrolled1 locationNCT07224971
Recruiting
Phase 3

Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC(SYNSTAR01)

EGFR-mutated Locally Advanced or Metastatic NSCLC
CSPC Megalith Biopharmaceutical Co.,Ltd.380 enrolled1 locationNCT06927986
Recruiting
Phase 1

A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

Locally Advanced or Metastatic NSCLC
Jiangsu Hansoh Pharmaceutical Co., Ltd.230 enrolled1 locationNCT06461156
Recruiting
Phase 3

Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC

NSCLC (Non-small Cell Lung Carcinoma)First Line TherapyLocally Advanced/Metastatic NSCLC
Dr Arvindran A/L Alaga123 enrolled1 locationNCT07050043
Recruiting
Phase 2Phase 3

De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction

Metastatic NSCLC
Intergroupe Francophone de Cancerologie Thoracique1,360 enrolled44 locationsNCT05255302
Recruiting

Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT : the MEKANOS Study

Metastatic Breast CancerMetastases to BoneMetastatic NSCLC
Hospices Civils de Lyon220 enrolled12 locationsNCT04170634
Recruiting
Phase 1Phase 2

Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

Advanced or Metastatic NSCLC
Jiangsu Hansoh Pharmaceutical Co., Ltd.354 enrolled1 locationNCT05435248
Recruiting

Patient's Whole Process Follow-up Management(HOPE-1)

Metastatic NSCLCLocally Advanced Non-Small Cell Lung Cancer
Qianfoshan Hospital1,268 enrolled1 locationNCT05339568